Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06023459 · ClinicalTrials.gov registry record · Phase 3
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
A Phase 3 study of Substance-Related Disorders and Opioid-Related Disorders, sponsored by Yih-Ing Hser.
- Active
- Registry status
- Phase 3
- Development phase
- 144
- Enrollment target
- 7
- Study locations
NCT06023459: Active Phase 3 study of Substance-Related Disorders and Opioid-Related Disorders, sponsored by Yih-Ing Hser.
NCT06023459 is a Phase 3 study of Substance-Related Disorders and Opioid-Related Disorders that is active but no longer recruiting, run by Yih-Ing Hser. The registered enrollment target is 144 participants, below the 1,519-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06023459, a Phase 3 study of Substance-Related Disorders and Opioid-Related Disorders, is active but no longer recruiting, sponsored by Yih-Ing Hser.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 144 participants
- Enrollment target
- 7
- Study locations
Study Summary
This pilot trial will explore the feasibility, acceptability, and effectiveness of the most recently approved formulation of injectable extended-release buprenorphine (XR-BUP) for treatment of opioid use disorder (OUD) in rural settings. We will randomize 144 eligible individuals with moderate to severe OUD in a 2:1 ratio to one of two medication conditions: (1) XR-BUP (128mg target), administered every 4 weeks or (2) SL-BUP (16mg-24 mg/day target).Participants will receive study medication treatment for the 14 week-intervention period, including an initial \~2-week period of induction/stabilization. The study will use a mixed-methods approach (participant assessments, study medication records, qualitative interviews) for assessing feasibility and acceptability, and results will include patient outcome data on the comparative effectiveness of XR-BUP versus SL-BUP for patients with OUD in rural settings.
Primary Outcome
Number of urine drug screen (UDS) results negative for opioids
Conditions Studied
Interventions
- DRUG Injectable extended-release buprenorphine
- DRUG Sublingual buprenorphine-naloxone
Study Locations (7)
Arkansas
- AppleGate Recovery El Dorado - El Dorado
California
- Southern Humboldt Community Healthcare District - Jerold Phelps Community Hospital - Garberville
Illinois
- Gibson Area Hospital and Health Services - Gibson Recovery Optimizing Wellness - Gibson City
Maine
- Penobscot Community Health Care Inc. - Seaport Community Health Center - Belfast
Oregon
- Oregon Health & Science University Primary Care Clinic, Scappoose - Scappoose
Washington
- Providence Northeast Washington Medical Group - Colville
West Virginia
- New Beginnings Recovery Clinic & Behavioral Health Center - New Martinsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 3 |
What the registry record for NCT06023459 still lists
NCT06023459 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 1,519-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Injectable extended-release buprenorphine is the first listed.
NCT06023459 lists 7 locations in 7 states (Arkansas, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT06023459 about?
NCT06023459 is a clinical study titled "Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)". This pilot trial will explore the feasibility, acceptability, and effectiveness of the most recently approved formulation of injectable extended-release buprenorphine (XR-BUP) for treatment of opioid use disorder (OUD) in rural settings. We will randomize 144 eligible individuals with moderate to se...
What is the current status of trial NCT06023459?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 144 participants. The study started on 2024-10-14. Estimated completion is 2026-02-28.
What conditions does trial NCT06023459 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Opioid-Related Disorders, Narcotic-Related Disorders.
What interventions are being tested in trial NCT06023459?
The interventions under investigation include: Injectable extended-release buprenorphine (DRUG), Sublingual buprenorphine-naloxone (DRUG).
Who is sponsoring clinical trial NCT06023459?
This trial is sponsored by Yih-Ing Hser, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06023459 being conducted?
This trial has 7 study locations across Arkansas, California, Illinois, Maine, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06023459's enrollment target sits among peer trials
144 28th of 58 higher than 31 of 58 other Substance-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Motivational Enhancement Therapy to Improve Treatment Utilization in Pregnant Substance Users - 1
COMPLETED · Phase 3
-
Integrated Cognitive Behavioral Therapy (ICBT) for Posttraumatic Stress Disorder (PTSD) and Substance Use Disorders
COMPLETED · Phase 3
-
Women's Treatment for Trauma and Substance Use Disorders - 1
COMPLETED · Phase 3
-
Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment
COMPLETED · Phase 3
-
Job-Seekers Training for Patients With Drug Dependence - 1
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI